Investment opportunity: Neoantigen cancer vaccines to prevent tumor recurrence

YGION Biomedical is developing neoantigen based vaccines to prevent cancer recurrence post-surgery.  

Our proprietary neoantigen discovery platform YGNITE™ combines next generation sequencing and in house bioinformatics to identify tumor neoantigens.  Neoantigen peptides are combined with our proprietary vaccine technology CARGONAUT™ which breaks tolerance and triggers a fast and superior anti-tumor response compared to other approaches.

Lead program YG-01 is a fully individualized vaccine and will enter Phase 1 clinical testing in Q1 2026.  Follow on program YG-02 targets shared neoantigens and is in discovery.

We are seeking €10M Series A2 financing to:

• Complete first-in-human testing of YG-01 in Glioblastoma to demonstrate safety, immunogenicity and indicators of clinical indicator of efficacy by 2029

• Expansion of preclinical proof-of-concept for further cancer indications for YG-01

• Expand pipeline with preclinical development of follow-up program YG-02 targeitng shared neoantigens

Why YGION?

• Phase 1 ready asset:  Preclinical proof-of-concept, completed GLP toxicology and GMP manufacture complete for YG-01

• Lean development plan to indicators of clinical efficacy within 3 years

• Patent protected proprietary and differentiated neoantigen vaccine technologies 

• Application across multiple cancer types: with multi $B market opportunity

• Experienced team:  Management and advisory co-founder team with extensive biotech/Pharma leadership experience